Numerous researchers began to concentrate on tissue engineering as a strategy to enhance the performance of present biologic grafts as a result of the frequent failures of commercially accessible xenografts and allografts. These innovative transplant ideas intend to use the patient's own cells developed on various structural supports. With Vascular Grafts, the immunogenicity and tendency for infection that have dogged many biologic grafts could be eliminated.
Different scaffold systems have been tested by a variety of researchers, who have also produced in vitro and animal models for Vascular Grafts. Despite these developments, the ideal tissue-engineered vascular transplant remains elusive. The Lifeline vascular graft for use in humans was created by Cytograft Tissue Engineering, Inc. (Novato, California), a company that has been actively engaged in this area of research and has integrated their innovative sheet-based tissue engineering scaffold.
